Results 1 to 10 of about 150,246 (305)

Postoperative complications after esophagectomy for cancer, neoadjuvant chemoradiotherapy compared to neoadjuvant chemotherapy: A single institutional cohort study

Clinical and Translational Radiation Oncology, 2023
Background: Complications after esophagectomy are common and the possible increase in postoperative complications associated with neoadjuvant chemoradiotherapy is of concern.
Halla Sif Ólafsdóttir, Emmy Dalqvist, Eva Onjukka, Fredrik Klevebro, Magnus Nilsson, Giovanna Gagliardi, Gabriella Alexandersson von Döbeln   +6 more
doaj   +1 more source

Neoadjuvant chemotherapy for breast cancer

Annals of Medicine, 2000
Primary or neoadjuvant chemotherapy in early breast cancer offers the chance to use the tumour as an in vivo measure of response, with the additional possibility of downstaging and avoidance of mastectomy. Tumour response to preoperative chemotherapy correlates with the outcome and could be a surrogate for evaluating the effect of chemotherapy on ...
F, Sapunar, I E, Smith
openaire   +2 more sources

Recent Advances and Hot Spots of Neoadjuvant Immunotherapy Combined with Chemotherapy for Esophageal Carcinoma

Zhongliu Fangzhi Yanjiu
Surgery-based multidisciplinary comprehensive treatment is the preferred treatment strategy for local advanced esophageal cancer. Neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy have been recommended by the Chinese Society of Clinical Oncology
Huilai LYU, Chunyue GAI, Mingbo WANG, Zhenhua LI, Jiachen LI, Shi XU, Weilu DING, Yu LIU, Ziqiang TIAN   +8 more
doaj   +1 more source

Role of immunotherapy in localized muscle invasive urothelial cancer

Therapeutic Advances in Medical Oncology, 2021
The standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy or trimodality therapy with chemoradiation in select patients.
Jasmeet Kaur, Woonyoung Choi, Daniel M. Geynisman, Elizabeth R. Plimack, Pooja Ghatalia   +4 more
doaj   +1 more source

Perioperative chemotherapy use and related outcomes in muscle‐invasive bladder cancer in Australia

BJUI Compass
Objectives To explore Australian data on perioperative chemotherapy use and associated outcomes in muscle‐invasive bladder cancer (MIBC). Subjects and Methods An observational study of patients with MIBC treated with neoadjuvant chemotherapy, adjuvant ...
Alison Hiong, James Lynam, Andrew Weickhardt, Shirley Wong, Shomik Sengupta, Paul Manohar, Lih‐Ming Wong, Philip Dundee, Nathan Lawrentschuk, Alison Y. Zhang, Angelyn Anton, Ajay Raghunath, Peter Gibbs, Ben Tran   +13 more
doaj   +1 more source

Neoadjuvant chemotherapy is not necessarily applicable to patients with LN1-3 positive Luminal-B type operable breast cancer

Scientific Reports
The purpose of is to identify the necessity of neoadjuvant chemotherapy in luminal type breast cancer patients (HR-positive HER2-negative) by exploring the treatment characteristics, treatment plan, surgical choice and long-term prognosis between ...
Tiantian Tang, Cong Wang, Xin Lv, Zhigang Fan, Hanxiao Ren, Yuntao Li   +5 more
doaj   +1 more source

Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients

BMC Cancer, 2006
Background There is a lack of clinical data on the validity of neoadjuvant chemotherapy in the treatment of ovarian cancer. The aim of this study was to compare the impact of the adjuvant and neoadjuvant chemotherapy regimens on the clinical outcomes in ...
Nadisauskiene Ruta, Kurtinaitis Juozas, Juozaityte Elona, Simavicius Andrius, Inciura Arturas, Svedas Eimantas, Kajenas Skirmantas   +6 more
doaj   +1 more source

Proteomic profiling identifies muscle-invasive bladder cancers with distinct biology and responses to platinum-based chemotherapy

Nature Communications
Platinum-based neoadjuvant chemotherapy prior to radical cystectomy is the preferred treatment for muscle-invasive bladder cancer despite modest survival benefit and significant associated toxicities.
A. Contreras-Sanz, G. L. Negri, M. J. Reike, H. Z. Oo, J. M. Scurll, S. E. Spencer, K. Nielsen, K. Ikeda, G. Wang, C. L. Jackson, S. Gupta, M. E. Roberts, D. M. Berman, R. Seiler, G. B. Morin, P. C. Black   +15 more
doaj   +1 more source

Avoidance and Period-Shortening of Neoadjuvant Chemotherapy Against Triple-Negative Breast Cancer in Stages I and II: Importance of Ki-67 Labeling Index and the Recognition of Apocrine-Type Lesions

Technology in Cancer Research & Treatment, 2020
Background: Triple-negative breast cancer encompasses heterogeneous subtypes. Neoadjuvant chemotherapy is ineffective against some triple-negative breast cancers, while others show a favorable prognosis despite chemoresistance.
Koichi Kubouchi MD, Kyosuke Shimada MD, Takamichi Yokoe MD, Yutaka Tsutsumi MD   +3 more
doaj   +1 more source

Neoadjuvant chemotherapy for advanced ovarian cancer

International Journal of Gynecology & Obstetrics, 1994
The purpose of this study was to compare the survival of women with clinical, radiologic, and histologic findings compatible with advanced ovarian cancer who were treated with neoadjuvant chemotherapy to that of a group of women with FIGO stage IIIC (suboptimal debulking) and stage IV epithelial ovarian cancers treated with the same chemotherapy ...
P E, Schwartz, J T, Chambers, R, Makuch
openaire   +2 more sources